The manufacturer of a breast cancer drug that offers a last hope to patients could have been "more flexible" to help make the drug affordable for the NHS, a health service boss said.
Sir Andrew Dillon, chief executive of the NHS financial watchdog Nice, which has ruled Kadcyla is too expensive for NHS use, said:
Although Roche proposed a discount to the full list price of Kadcyla, it made little difference to its value for money, leaving it well above the top of our specially extended range of cost effectiveness for cancer drugs.
We are really disappointed that Roche were not able to demonstrate more flexibility to help us make a positive recommendation. The company is well aware that we could not have recommend Kadcyla at the price it proposed.
More top news
Showers across Britain will make way for sunshine tomorrow before a milder end to the weekend, though heavy rain will return in the north.
George Clooney appeared in a special Downton Abbey as a host of stars came together to raise money for the ITV charity campaign Text Santa.
Events company Secret Cinema is planning to screen a film in protest at what they have called the 'censorship' of The Interview.